Whilst there is significant interest in therapeutically targeting the pro-tumorigenic functions of JNK in various cancers, the pleotropic nature of JNK signaling means that direct JNK inhibition may have adverse consequences and is unlikely to yield clinically viable cancer treatments. The gene discussed is MAPK8; the disease is cancer.